HC Wainwright Analysts Boost Earnings Estimates for ARQT

Key Points

• HC Wainwright raised its Q3 2026 EPS estimate for Arcutis Biotherapeutics to $0.17 from $0.06, while projecting full-year 2026 EPS of $0.44 and continued earnings growth through 2030.
• Arcutis reported quarterly EPS of $0.11, beating the $0.06 consensus, while revenue reached $129.86 million versus estimates of $118.85 million. Management also raised 2026 net product-sales guidance to $525 million–$540 million.
• Analyst sentiment remains favorable: six analysts rate ARQT a Buy and three rate it a Hold, producing a consensus “Moderate Buy” rating and a $35.57 price target.

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) - Stock analysts at HC Wainwright increased their Q3 2026 earnings per share estimates for shares of Arcutis Biotherapeutics in a research note issued on Thursday, August 6th. HC Wainwright analyst D. Tsao now forecasts that the company will earn $0.17 per share for the quarter, up from their previous estimate of $0.06. The consensus estimate for Arcutis Biotherapeutics' current full-year earnings is $0.33 per share. HC Wainwright also issued estimates for Arcutis Biotherapeutics' Q4 2026 earnings at $0.25 EPS, FY2026 earnings at $0.44 EPS, FY2027 earnings at $1.00 EPS, FY2028 earnings at $1.66 EPS, FY2029 earnings at $2.07 EPS and FY2030 earnings at $2.36 EPS.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last posted its earnings results on Wednesday, August 5th. The company reported $0.11 EPS for the quarter, topping analysts' consensus estimates of $0.06 by $0.05. Arcutis Biotherapeutics had a return on equity of 15.05% and a net margin of 6.15%.The business had revenue of $129.86 million during the quarter, compared to analyst estimates of $118.85 million.

ARQT has been the subject of several other reports. Wall Street Zen upgraded Arcutis Biotherapeutics from a "buy" rating to a "strong-buy" rating in a report on Saturday. Needham & Company LLC upped their target price on shares of Arcutis Biotherapeutics from $36.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday. Weiss Ratings raised shares of Arcutis Biotherapeutics from a "sell (d-)" rating to a "hold (c-)" rating in a report on Thursday. Morgan Stanley lifted their price target on shares of Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an "overweight" rating in a research note on Thursday. Finally, Guggenheim boosted their price objective on shares of Arcutis Biotherapeutics from $35.00 to $38.00 and gave the company a "buy" rating in a report on Thursday. Six equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, Arcutis Biotherapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $35.57.

Arcutis Biotherapeutics Stock Performance

Shares of NASDAQ:ARQT opened at $25.29 on Monday. The company has a market cap of $3.18 billion, a P/E ratio of 120.43 and a beta of 1.49. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.92 and a quick ratio of 2.67. Arcutis Biotherapeutics has a 1 year low of $13.69 and a 1 year high of $31.77. The stock's fifty day moving average price is $26.05 and its 200-day moving average price is $24.68.

Institutional Trading of Arcutis Biotherapeutics

Several large investors have recently added to or reduced their stakes in the business. Suvretta Capital Management LLC raised its position in Arcutis Biotherapeutics by 14.2% in the fourth quarter. Suvretta Capital Management LLC now owns 11,964,000 shares of the company's stock worth $347,435,000 after acquiring an additional 1,486,000 shares during the period. BlackRock Inc. purchased a new position in shares of Arcutis Biotherapeutics during the 2nd quarter worth $276,502,000. Vanguard Group Inc. grew its position in shares of Arcutis Biotherapeutics by 1.5% during the 4th quarter. Vanguard Group Inc. now owns 7,253,936 shares of the company's stock valued at $210,654,000 after acquiring an additional 107,846 shares during the period. Polar Capital Holdings Plc grew its position in shares of Arcutis Biotherapeutics by 4.9% during the 4th quarter. Polar Capital Holdings Plc now owns 5,556,169 shares of the company's stock valued at $161,351,000 after acquiring an additional 257,415 shares during the period. Finally, State Street Corp raised its holdings in Arcutis Biotherapeutics by 18.2% in the 4th quarter. State Street Corp now owns 5,488,301 shares of the company's stock worth $159,380,000 after purchasing an additional 846,986 shares during the period.

Insider Transactions at Arcutis Biotherapeutics

In other news, Director Sue-Jean Lin sold 4,946 shares of the company's stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.38, for a total transaction of $120,583.48. Following the completion of the sale, the director owned 27,567 shares of the company's stock, valued at $672,083.46. This represents a 15.21% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Masaru Matsuda sold 1,230 shares of the stock in a transaction that occurred on Monday, August 3rd. The stock was sold at an average price of $26.12, for a total transaction of $32,127.60. Following the completion of the transaction, the insider owned 126,171 shares in the company, valued at $3,295,586.52. This trade represents a 0.97% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 16,237 shares of company stock worth $408,214 in the last ninety days. Insiders own 9.40% of the company's stock.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Strong second-quarter performance: Arcutis reported adjusted EPS of $0.11, exceeding estimates of $0.06–$0.09 and improving from a $0.13 loss a year earlier. Revenue rose 59% year over year to $129.9 million, beating the $118.9 million consensus estimate. Arcutis Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Raised sales outlook and expanding ZORYVE opportunity: Management increased 2026 net product-sales guidance to $525 million–$540 million. ZORYVE also gained an expanded pediatric plaque-psoriasis approval, while the FDA accepted an application for use in infants with atopic dermatitis. Arcutis Second-Quarter 2026 Financial Results
• Positive Sentiment: Analyst support remains favorable: Needham raised its price target from $36 to $40 and reiterated a Buy rating. HC Wainwright’s 2027 estimates project quarterly EPS rising from $0.08 in the first quarter to $0.48 in the fourth quarter, suggesting expectations for continued earnings growth. Benzinga analyst report
• Neutral Sentiment: Commercial leadership changes: Arcutis announced key changes to its commercial leadership team. The move could support execution, but investors may initially view management transitions as an operational uncertainty. Arcutis Announces Key Commercial Leadership Changes
• Neutral Sentiment: Insider selling was limited and prearranged: Three executives sold a combined 6,560 shares to cover tax withholding on vested equity awards under Rule 10b5-1 plans, reducing the bearish significance of the transactions.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source